These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25495491)

  • 41. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
    Jakesz R
    MMW Fortschr Med; 2005 Mar; 147(10):8. PubMed ID: 15803774
    [No Abstract]   [Full Text] [Related]  

  • 43. Breast cancer (metastatic).
    Stebbing J; Glassman R
    Clin Evid; 2004 Jun; (11):2266-99. PubMed ID: 15652111
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeting breast cancer with hormonal treatment options.
    Mellington TE; Fields MM
    Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
    [No Abstract]   [Full Text] [Related]  

  • 45. Estrogen and progesterone receptors in breast cancer.
    Ma CX
    Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
    [No Abstract]   [Full Text] [Related]  

  • 46. The evolving role of exemestane in the management of breast cancer.
    Bundred N
    Br J Hosp Med (Lond); 2006 Aug; 67(8):427-30. PubMed ID: 16918105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 62-year-old woman with a new diagnosis of breast cancer.
    Come SE
    JAMA; 2006 Mar; 295(12):1434-42. PubMed ID: 16551716
    [No Abstract]   [Full Text] [Related]  

  • 48. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 49. Are SOFT and TEXT results practice changing and how?
    Pagani O; Regan MM; Francis PA
    Breast; 2016 Jun; 27():122-5. PubMed ID: 27107153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
    Gemignani ML; Hetzel DJ
    Gynecol Oncol; 2017 Oct; 147(1):153-157. PubMed ID: 28662774
    [No Abstract]   [Full Text] [Related]  

  • 51. Breast cancer (metastatic).
    Stebbing J; Crane J; Gaya A
    Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
    [No Abstract]   [Full Text] [Related]  

  • 52. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
    Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
    Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant treatment of breast cancer with exemestane.
    Tanvetyanon T
    N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
    [No Abstract]   [Full Text] [Related]  

  • 54. [New options in adjuvant endocrine therapy in breast cancer].
    Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
    Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial.
    Baum M
    Cancer Control; 2004; 11(4):217-21. PubMed ID: 15284712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Aromatase inhibitors in adjuvant setting in breast cancer].
    Spano JP; Khayat D; Delozier T
    Bull Cancer; 2004 Dec; 91 Suppl 4():S239-43. PubMed ID: 15899615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
    Chlebowski RT; Col N
    Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
    Fabian CJ
    Int J Clin Pract; 2007 Dec; 61(12):2051-63. PubMed ID: 17892469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
    Ravdin P
    Lancet; 2002 Jun; 359(9324):2126-7. PubMed ID: 12090973
    [No Abstract]   [Full Text] [Related]  

  • 60. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
    Herold CI; Blackwell KL
    Clin Breast Cancer; 2008 Feb; 8(1):50-64. PubMed ID: 18501059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.